Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies

Evaluation of a Cosmetic Product (Onco-Rash) to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies Which Are Known to Fragilize Epidermis

It is important for patients treated with anti-EGFR therapies to get access to cosmetic options to preserve their skin condition during treatment. Anti-EGFR therapies are known to fragilize epidermis and to provoke rashes; which often lead to treatment discontinuation.

The aim of this study is to demonstrate that the Onco-Rash cream is able to preserve skin condition without side effects. Decreasing skin toxicity is expected to improve patients' life and facilitate treatment follow-up.

Inclusion Criteria:

• Patient > 18 years old
• Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc).
• NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc)
• Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….)
• Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…)
• Signed informed consent
• Social security affiliation

Exclusion Criteria:

• Pregnant or Breastfeeding patient
• Patient in age to procreate without an efficient contraceptive method
• Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product
• Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR
• Patients under radiotherapy 8 days prior the inclusion date
• Patient under immunotherapy 8 days prior the inclusion date
• Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date
• Patient with antihistamines treatment 8 days prior the inclusion date
• Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date
• Participation to another interventional study
• Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( >2)
• Patient deprived of liberty or subjected to guardianship
• Impossibility to track and follow patient for geographical, social or psychiatric reasons.